Aggressive Prostate Cancers in Elderly Patients

Prostatic Neoplasms Clinical Trial

Official title:

Patients Aged More Than 70 Had More Aggressive Prostate Cancers and Higher Risk of Biochemical Recurrence in Korea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01347476
• Other study ID #: old age prostate
• Secondary ID: elderly pts with
• Status: Completed
• Phase: N/A
• First received: April 29, 2011
• Last updated: May 18, 2011
• Start date: January 2010
• Est. completion date: October 2010

Study information

• Verified date: May 2011
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Patients aged 70 years or older had a higher possibility of high risk cancer than younger patients.

Description:

Patients aged 70 years or older had a higher risk of advanced prostate cancer and shorter BCR-free survival than younger ones. Definite treatment of clinically localized prostate cancer should be actively considered in well-selected healthy patients older than 70 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1333
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• clinically localized prostate cancer

• good health status

• follow-up period more than 12 months

Exclusion Criteria:

• insufficient clinical data

• poor health status

• clinically advanced prostate cancer

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Prostatic Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Boramae Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	biochemical recurrences (BCR)	BCR was defined as two consecutive increasing PSA values of more than 0.2 ng/mL	5 year-BCR	No
Secondary	pathologic outcomes	biopsy or pathologic Gleason scores, mean percent of positive cores and tumor volume percent, Extracapsular extension and seminal vesicle invasion	postoperative 1 week	No